WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012045063) FLAVIVIRUS DOMAIN III VACCINE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/045063    International Application No.:    PCT/US2011/054531
Publication Date: 05.04.2012 International Filing Date: 03.10.2011
IPC:
A61K 39/00 (2006.01), A61K 39/12 (2006.01), C07K 1/00 (2006.01), C12N 15/00 (2006.01), C12P 21/06 (2006.01), C07H 21/04 (2006.01)
Applicants: UNIVERSITY OF ROCHESTER [US/US]; 601 Elmwood Avenue, Box Ott Rochester, NY 14642 (US) (For All Designated States Except US).
SCHLESINGER, Jacob, J. [US/US]; (US) (For US Only).
JIN, Xia [US/US]; (US) (For US Only).
ROSE, Robert, C. [US/US]; (US) (For US Only).
BLOCK, Olivia, K., T. [US/US]; (US) (For US Only).
RODRIGO, Shanaka I., W., W. [LK/LK]; (LK) (For US Only)
Inventors: SCHLESINGER, Jacob, J.; (US).
JIN, Xia; (US).
ROSE, Robert, C.; (US).
BLOCK, Olivia, K., T.; (US).
RODRIGO, Shanaka I., W., W.; (LK)
Agent: MERKEL, Edwin, V.; LeClairRyan 70 Linden Oaks, Suite 210 Rochester, NY 14625 (US)
Priority Data:
61/388,780 01.10.2010 US
Title (EN) FLAVIVIRUS DOMAIN III VACCINE
(FR) VACCIN CONTRE LE FLAVIVIRUS DU DOMAINE III
Abstract: front page image
(EN)The disclosure provides a tetravalent Dengue virus vaccine, and methods of inducing a immune response against a Flavivirus such as Dengue virus 1-4 using the vaccine. The disclosure also provides methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dill polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses.
(FR)La présente invention concerne un vaccin tétravalent contre le virus de la dengue, des méthodes d'induction d'une réponse immunitaire neutralisante contre un flavivirus tel que le virus de la dengue 1-4. L'invention concerne également des méthodes de fabrication d'un vaccin par introduction dans une cellule hôte d'un transgène codant une protéine comprenant des polypeptides de la dengue du domaine III ou, par des polypeptides d'aneth purifié spécifiques pour les sérotypes de la dengue 1-4, le virus de la fièvre jaune, le virus du Nil occidental, le virus de l'encéphalite japonaise, et les flavivirus.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)